Return to Genitourinary Cancer Specialty Channel

Genitourinary Cancer Interactive Features

What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
True or false: Ipilimumab plus nivolumab did not demonstrate activity in patients with metastatic RCC previously given immune checkpoint inhibitors.
True or False: Enfortumab vedotin monotherapy has not been shown to yield durable responses in patients with metastatic urothelial cancer.
True or false: Teratoma is a prognostic factor in patients with metastatic testicular germ cell tumors.
True or False: Combining nivolumab therapy with ipilimumab has shown long-term benefit in advanced RCC.
True or False: Erdafitinib is tied to an objective response in 40% of patients with locally advanced or metastatic urothelial cancer with FGFR alterations.
True or false: In a recent study, nivolumab yielded no antitumor activity whether administered alone or in combination with ipilimumab in patients with metastatic urothelial carcinoma.
Stay in the know.
OncNet Newsletter